Welcome to the ABLAVAR™ Web site
The introduction of ABLAVAR™(gadofosveset trisodium)—the first FDA-approved gadolinium (Gd)-based blood-pool contrast agent for magnetic resonance angiography (MRA)—heralds an intriguing new era in MRA for evaluation of aortoiliac occlusive disease (AIOD) in patients with suspected peripheral vascular disease.1,2
Only ABLAVAR™ provides an expanded imaging window of up to 1 hour, which enables you to obtain high-resolution first-pass and steady-state MRA images that provide a level of diagnostic accuracy that is comparable to that of conventional X-ray angiography (XRA).1 And these images are acquired with a single, low-dose injection of ABLAVAR™.
Throughout this Web site, you will learn more about the unique attributes of ABLAVAR™ that make it the logical next step in MRA.
- The ABLAVAR™ difference
- What is a blood-pool agent?
- Clinical utilization of ABLAVAR™ in real-world MRA
At long last, ABLAVAR™ is available to US radiologists and technologists. Thank you for taking the time to discover the ABLAVAR™ difference for yourself.
References
1. ABLAVAR™ [package insert]. North Billerica, MA: Lantheus Medical Imaging, Inc.; 2009. 2. U.S. Food and Drug Administration Web Site. http://www.fda.gov/drugs. Accessed September 28, 2009.
INDICATIONS:
ABLAVAR™ is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease.
CONTRAINDICATIONS:
History of a prior allergic reaction to a gadolinium-based contrast agent.
IMPORTANT SAFETY INFORMATION:
WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF)
Gadolinium-based contrast agents increase the risk of nephrogenic systemic fibrosis (NSF) in patients with:
- acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2), or
- acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period.
In these patients, avoid use of gadolinium-based contrast agents unless the diagnostic information is essential and not available with non-contrast enhanced magnetic resonance imaging (MRI). NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle, and internal organs. Screen all patients for renal dysfunction by obtaining a history and/or laboratory tests. When administering a gadolinium-based contrast agent, do not exceed the recommended dose and allow a sufficient period of time for elimination of the agent from the body prior to any re-administration.
ABLAVAR™ Injection: As with other contrast media: the possibility of serious or life-threatening anaphylactic or anaphylactoid reactions, including cardiovascular, respiratory and/or cutaneous manifestations, should always be considered. As with other paramagnetic contrast agents, caution should be exercised in patients with renal insufficiency due to the possibility of further deterioration in renal function.
In clinical trials, a small increase (2.8 msec) in the average change from baseline in QTc was observed at 45 minutes. These QTc prolongations were not associated with arrhythmias or symptoms. Caution should be used in patients at high risk for arrhythmias due to baseline QTc prolongation.
Have emergency resuscitative equipment available prior to and during ABLAVAR™ administration.
This site is intended for US Healthcare Professionals only.
ABLAVAR is a trademark of Lantheus Medical Imaging, Inc. Use of the information on this site is subject to the terms of our Legal Notice and Privacy Policy.
© 2010 Lantheus Medical Imaging, Inc. All Rights Reserved.